Abstract
In this article, we will discuss how treatment strategies for myeloma have evolved and outline the challenges now faced following the introduction of a number of novel active agents. In particular, we will focus on how achieving a maximum response and maintaining such responses is becoming a key therapeutic strategy and how novel agents can be used to achieve this in the context of current strategies such as autologous transplantation.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols
-
Boronic Acids / therapeutic use
-
Bortezomib
-
Clinical Trials as Topic
-
Humans
-
Multiple Myeloma / drug therapy*
-
Protease Inhibitors / therapeutic use
-
Pyrazines / therapeutic use
-
Thalidomide / therapeutic use
Substances
-
Angiogenesis Inhibitors
-
Boronic Acids
-
Protease Inhibitors
-
Pyrazines
-
Thalidomide
-
Bortezomib